About
Bioquantis: Advancing AI-Driven Cardiology
Bioquantis is the result of a unique collaboration between experts in cardiology and data science, united by a common mission: anticipating diagnoses to improve patient health. Born from academic research, Bioquantis leverages its extensive experience in clinical research and the power of artificial intelligence to develop predictive tools and diagnostic support solutions for cardiac diseases.
Initially, Bioquantis focused on conducting epidemiological analyses of coronary artery disease, building expertise in clinical epidemiology, biostatistics, and risk prediction. Today, we translate this expertise into real-world clinical applications, providing cutting-edge AI-powered solutions for cardiologists.
Our flagship innovation is an AI-assisted software designed to enhance the echocardiographic screening of transthyretin cardiac amyloidosis (aTTR). By integrating AI into clinical workflows, Bioquantis empowers healthcare professionals with faster, more accurate, and more efficient diagnostic tools, transforming the future of cardiology.
experts
Our leadership team
Yedid Elbez, Co-founder
Chief Technical Officier
Pr. Gabriel Steg, Co-founder
Chief Medical Officer
Pr. Gregory Ducrocq, Co-founder
Chief Clinical Officer
Catherine Dahlen
Chief Financial Officer
Pr. Vincent Algalarrondo
Head of the cardiac amyloidosis reference center, Bichat Hospital
Isabelle Wekstein
Lawyer at court, partner of WAN law firm
Oumaya Ibrahimi
Chief Regulatory Officer
Helene Abergel
Clinical Project Manager
